Alsarraje, H., Khalel Alhyali, L. (2023). Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats. Egyptian Journal of Histology, 46(4), 1893-1899. doi: 10.21608/ejh.2022.154514.1745
Hadeel Anwar Alsarraje; Liqaa Khalel Alhyali. "Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats". Egyptian Journal of Histology, 46, 4, 2023, 1893-1899. doi: 10.21608/ejh.2022.154514.1745
Alsarraje, H., Khalel Alhyali, L. (2023). 'Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats', Egyptian Journal of Histology, 46(4), pp. 1893-1899. doi: 10.21608/ejh.2022.154514.1745
Alsarraje, H., Khalel Alhyali, L. Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats. Egyptian Journal of Histology, 2023; 46(4): 1893-1899. doi: 10.21608/ejh.2022.154514.1745
Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats
2College of Medicine, University of Mosul, Mosul, Iraq
Abstract
Background and objective: We aimed to identify the effects of dienogest on inducing thromboembolism in rats following exposure to dienogest for a period of either 10 days (2 estrus cycles), 20 days (4 estrous cycles), or 30 days (6 estrus cycles). Materials and Methods: To do so, 40 rats were divided into 4 groups; dienogest-free control group, dienogest treated for 10 days (G1), 20 days (G2), and 30 days (G3). Then lungs and femoral veins were collected from subjects after sacrificing them, and these tissues were fixed for histological analysis. Results: Results showed that venous thromboembolism increased with dienogest therapy as indicated by the increased score of inflammation in the lung tissues, alongside increased thickness of femoral vein wall, and histological findings of fibrin deposition, vessel congestion, inflammatory cells infiltrations, and epithelial desquamation. Conclusion: To sum up, dienogest long-term therapy could be a risk for cardiac thrombotic diseases, and therefore we do advise using alternative progesterone or adding estrogen in low doses to minimize toxic effects primarily when used as postmenopausal replacement therapy.
View on SCiNiTO
Top